Arcus Historical Cash Flow

RCUS Stock  USD 10.89  1.01  10.22%   
Analysis of Arcus Biosciences cash flow over time is an excellent tool to project Arcus Biosciences future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 122.6 M or Other Cashflows From Financing Activities of 1.9 M as it is a great indicator of Arcus Biosciences ability to facilitate future growth, repay debt on time or pay out dividends.
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Arcus Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Arcus Biosciences is a good buy for the upcoming year.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcus Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
For more information on how to buy Arcus Stock please use our How to Invest in Arcus Biosciences guide.

About Arcus Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Arcus balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Arcus's non-liquid assets can be easily converted into cash.

Arcus Biosciences Cash Flow Chart

At this time, Arcus Biosciences' Change In Cash is comparatively stable compared to the past year. Stock Based Compensation is likely to gain to about 79.8 M in 2025, despite the fact that Free Cash Flow is likely to grow to (167.2 M).

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.
Most accounts from Arcus Biosciences' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Arcus Biosciences current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcus Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
For more information on how to buy Arcus Stock please use our How to Invest in Arcus Biosciences guide.At this time, Arcus Biosciences' Change In Cash is comparatively stable compared to the past year. Stock Based Compensation is likely to gain to about 79.8 M in 2025, despite the fact that Free Cash Flow is likely to grow to (167.2 M).

Arcus Biosciences cash flow statement Correlations

0.16-0.06-0.780.13-0.13-0.61-0.66-0.24-0.5-0.790.61-0.7-0.770.59-0.3-0.94-0.340.59-0.130.28
0.16-0.84-0.09-0.78-0.720.11-0.07-0.670.24-0.330.14-0.59-0.120.01-0.58-0.2-0.6-0.13-0.50.56
-0.06-0.84-0.150.690.58-0.47-0.160.52-0.510.120.020.32-0.120.210.280.010.620.410.59-0.25
-0.78-0.09-0.15-0.250.120.870.880.340.680.94-0.820.81.0-0.870.370.860.02-0.890.02-0.36
0.13-0.780.69-0.250.88-0.35-0.240.54-0.46-0.10.00.2-0.210.070.73-0.170.230.29-0.03-0.73
-0.13-0.720.580.120.88-0.050.170.5-0.30.27-0.460.430.16-0.350.830.140.250.01-0.11-0.81
-0.610.11-0.470.87-0.35-0.050.80.090.880.75-0.630.680.85-0.740.330.73-0.11-0.89-0.15-0.33
-0.66-0.07-0.160.88-0.240.170.80.170.470.87-0.870.720.88-0.810.290.80.1-0.720.06-0.27
-0.24-0.670.520.340.540.50.090.17-0.050.34-0.180.520.38-0.290.660.27-0.06-0.350.08-0.65
-0.50.24-0.510.68-0.46-0.30.880.47-0.050.53-0.290.520.64-0.470.160.53-0.14-0.79-0.09-0.17
-0.79-0.330.120.94-0.10.270.750.870.340.53-0.840.890.94-0.790.370.870.31-0.710.26-0.35
0.610.140.02-0.820.0-0.46-0.63-0.87-0.18-0.29-0.84-0.65-0.840.91-0.44-0.7-0.090.620.120.42
-0.7-0.590.320.80.20.430.680.720.520.520.89-0.650.8-0.60.60.780.41-0.610.33-0.58
-0.77-0.12-0.121.0-0.210.160.850.880.380.640.94-0.840.8-0.890.40.850.0-0.890.0-0.39
0.590.010.21-0.870.07-0.35-0.74-0.81-0.29-0.47-0.790.91-0.6-0.89-0.52-0.640.220.840.310.51
-0.3-0.580.280.370.730.830.330.290.660.160.37-0.440.60.4-0.520.3-0.05-0.42-0.31-1.0
-0.94-0.20.010.86-0.170.140.730.80.270.530.87-0.70.780.85-0.640.30.34-0.640.14-0.28
-0.34-0.60.620.020.230.25-0.110.1-0.06-0.140.31-0.090.410.00.22-0.050.340.380.760.08
0.59-0.130.41-0.890.290.01-0.89-0.72-0.35-0.79-0.710.62-0.61-0.890.84-0.42-0.640.380.290.42
-0.13-0.50.590.02-0.03-0.11-0.150.060.08-0.090.260.120.330.00.31-0.310.140.760.290.34
0.280.56-0.25-0.36-0.73-0.81-0.33-0.27-0.65-0.17-0.350.42-0.58-0.390.51-1.0-0.280.080.420.34
Click cells to compare fundamentals

Arcus Biosciences Account Relationship Matchups

Arcus Biosciences cash flow statement Accounts

202020212022202320242025 (projected)
Investments(431.3M)(28.8M)(413M)213M(84M)(88.2M)
Change In Cash115.5M(22.7M)58M(79M)23M24.2M
Stock Based Compensation22M55M65M73M76M79.8M
Free Cash Flow108.1M(282.2M)426M(330M)(176M)(167.2M)
Change In Working Capital208.1M(375.6M)623M(71M)22M20.9M
Begin Period Cash Flow58.1M173.6M151M209M130M122.6M
Total Cashflows From Investing Activities59.2M(434.4M)(3.9M)(413M)(371.7M)(353.1M)
Other Cashflows From Financing Activities4.7M12.3M33M8M2M1.9M
Depreciation4.2M3.8M6M8M10M5.3M
Other Non Cash Items(46K)3.5M11M(9M)5M5.3M
Capital Expenditures3.1M26.1M12M24M6M10.6M
Total Cash From Operating Activities111.2M(256.2M)438M(306M)(170M)(161.5M)
Change To Operating Activities531K21.3M14.1M23M26.5M27.8M
Net Income(122.9M)52.8M(267M)(307M)(283M)(268.9M)
Total Cash From Financing Activities1.1M438.7M237.3M33M277M162.2M
End Period Cash Flow173.6M150.9M209M130M153M135.6M
Other Cashflows From Investing Activities61.1M(431M)22M3M2.7M2.8M
Change To Netincome10.2M21.8M54.5M76M87.4M91.8M
Change To Liabilities3.3M24.1M4.9M(104M)(93.6M)(88.9M)
Change To Account Receivables(917K)(17.0M)704M15M28M26.6M
Issuance Of Capital Stock433.8M220.2M23M36M228M122.0M
Change To Inventory21.3M14.1M(704M)(15M)(13.5M)(14.2M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Arcus Stock Analysis

When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.